<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523844</url>
  </required_header>
  <id_info>
    <org_study_id>1992</org_study_id>
    <nct_id>NCT04523844</nct_id>
  </id_info>
  <brief_title>Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections</brief_title>
  <official_title>Effect of Topical Prophylaxis With Brinzolamide-brimonidine Fixed Combination on Intraocular Pressure Elevation After Intravitreal Injections of Anti-vascular Endothelial Growth Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Athens Elpis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Athens Elpis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine&#xD;
      fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal&#xD;
      injections of anti-vascular endothelial growth factors (anti-VEGF).&#xD;
&#xD;
      Patients scheduled for treatment with intravitreal injections of anti-VEGF will be randomly&#xD;
      divided into two groups. In control group no prophylactic medication will be used, whereas in&#xD;
      case group one drop of brinzolamide-brimonidine fixed combination will be instilled two hours&#xD;
      before the injection. IOP will be measured before the injection, 1 minute after the&#xD;
      injection, 10 minutes and 30 minutes post-injection in all eyes. In case group, the&#xD;
      pre-injection IOP will be measured prior to the administration of the fixed combination of&#xD;
      brinzolamide-brimonidine. The iCare (IC200) tonometer will be used for IOP measurements at&#xD;
      all time points.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intravitreal anti-VEGF (ranibizumab, bevacizumab, pegaptanib and aflibercept) are&#xD;
      commonly used in the treatment of diabetic macular edema, neovascular age-related macular&#xD;
      degeneration and other pathologies characterized by retinal or choroidal neovascularization.&#xD;
      Intravitreal injections Î¿f anti-VEGF agents result in an immediate and transient increase in&#xD;
      IOP, which returns to normal within a short period of time, typically within thirty minutes.&#xD;
      Repeated intravitreal injections and prolonged treatments seem to be associated with&#xD;
      sustained elevation of IOP, leading to the initiation of ocular hypotensive medication and&#xD;
      glaucoma filtration surgery. A fixed-dose combination of brinzolamide 1%, a carbonic&#xD;
      anhydrase inhibitor, and brimonidine 0,2%, an alpha 2 adrenergic receptor agonist, represents&#xD;
      a safe and effective drug in glaucoma treatment and its ocular hypotensive effect has been&#xD;
      demonstrated similar to or better than the unfixed combinations of its component drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigator who will measure the IOP will be masked to group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IOP at 1 minute post-injection</measure>
    <time_frame>1 minute post-injection</time_frame>
    <description>IOP will be measured by the same portable tonometer used before the injection (iCare-IC200 tonometer)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP at 10 minutes post-injection</measure>
    <time_frame>10 minutes post-injection</time_frame>
    <description>IOP will be measured by the same portable tonometer used before the injection (iCare-IC200 tonometer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP at 30 minutes post-injection</measure>
    <time_frame>30 minutes post-injection</time_frame>
    <description>IOP will be measured by the same portable tonometer used before the injection (iCare-IC200 tonometer)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Eye Diseases</condition>
  <condition>Injection Complication</condition>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Brinzolamide-brimonidine fixed combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No topical IOP-lowering medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No IOP-lowering drops are instilled before the intravitreal injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide-brimonidine Fixed Combination</intervention_name>
    <description>In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection</description>
    <arm_group_label>Brinzolamide-brimonidine fixed combination</arm_group_label>
    <other_name>Simbrinza 0.2%-1% Ophthalmic Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for treatment with intravitreal injections of anti-vascular&#xD;
             endothelial growth factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of glaucoma or ocular hypertension&#xD;
&#xD;
          -  use of topical medications (e.g. IOP-lowering medication, corticosteroids)&#xD;
&#xD;
          -  pseudoexfoliation&#xD;
&#xD;
          -  pigment dispersion syndrome&#xD;
&#xD;
          -  corneal diseases&#xD;
&#xD;
          -  active intraocular inflammation&#xD;
&#xD;
          -  any intraocular surgery in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Dettoraki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Elpis&quot; General Hospital of Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Elpis&quot; General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Ambelokipi</state>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Athens Elpis</investigator_affiliation>
    <investigator_full_name>Maria Dettoraki</investigator_full_name>
    <investigator_title>Locum Specialist, Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>anti-vascular endothelial growth factor</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>brinzolamide</keyword>
  <keyword>brimonidine</keyword>
  <keyword>fixed combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

